UCLA’s First-in-Class Heart Drug Shows Unexpected Kidney Repair Benefits in Mouse Studies, Published in Cell Stem Cell

June 20, 2026 | 5:00 AM IST

LOS ANGELES — A novel drug originally engineered to repair damaged heart tissue after a heart attack has demonstrated a surprising secondary superpower: healing damaged kidneys. In a laboratory study published Thursday in the peer-reviewed journal Cell Stem Cell, researchers revealed that the experimental medication, called AD-NP1, significantly accelerates tissue regeneration and reduces scarring in mice with acute kidney injuries. Developed entirely at the University of California, Los Angeles (UCLA), the drug recently cleared a major milestone by receiving U.S. Food and Drug Administration (FDA) approval for Phase 1 human clinical trials targeting heart repair. This new discovery suggests AD-NP1 could become a first-in-class therapy capable of enhancing tissue regeneration across multiple distinct organ systems.

The Breakthrough: Blocking the ENPP1 Traffic Jam

The research team, led by Lianjiu Su and colleagues at UCLA, uncovered that injured kidneys produce high levels of a specific protein called ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase-1). When an organ is damaged, healthy surrounding cells naturally try to multiply to heal the wound. However, the excess ENPP1 triggers a metabolic chain reaction that disrupts cellular energy production. Essentially, the injured tissue sends out a distress signal that accidentally paralyzes the kidney’s natural ability to regenerate.

AD-NP1 is a monoclonal antibody—a laboratory-engineered protein designed to mimic the immune system’s natural antibodies. It was specifically built to target and lock onto human ENPP1 without disturbing any other proteins. By blocking ENPP1, the drug effectively cuts off the inhibitory signal, clearing the way for cells to safely divide and rebuild.

To test this, the researchers looked at the effects of ENPP1 in two ways:

• Genetic Modification: They compared normal mice to mice genetically modified to lack the ENPP1 protein. While both groups initially suffered similar kidney damage, weeks later, the mice lacking ENPP1 showed significantly better tissue repair, vastly improved kidney function, and minimal scarring.

• Antibody Treatment: In a separate trial, researchers induced kidney damage in normal mice and then administered a single dose of AD-NP1. Just seven days later, the treated mice exhibited starkly improved kidney function and far less structural scarring compared to untreated controls.

“These animals had a far better outcome,” noted Dr. Arjun Deb, a UCLA professor of medicine and molecular, cell, and developmental biology, and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. “Their kidneys were not as damaged, and the kidney cells were proliferating more.”

Mechanisms That Cross Organ Boundaries

The discovery came as a surprise to the scientific team, who initially focused solely on cardiovascular health. “We discovered that the mechanisms we identified in the heart were also relevant in the kidney,” Dr. Deb explained.

Using advanced tools like single-cell transcriptomics (a method that maps out which genes are active in individual cells) and metabolic profiling, the researchers watched the healing process unfold at a microscopic level. A single dose of the antibody successfully rescued cell cycle arrest—a state where cells get stuck and cannot divide—allowing essential tubular cells in the kidney to multiply and replace dead tissue.

Because cellular energy pathways are remarkably consistent across different parts of the body, interrupting the ENPP1 roadblock seems to act as a universal green light for healing, whether the damage is located in the cardiac muscle or the renal tubules.

Acute Kidney Injury: A Growing Global Crisis

The potential public health implications of a drug that actively repairs kidney tissue are massive. Currently, modern medicine has zero approved medications that can actively regenerate tissue or enhance repair after an episode of Acute Kidney Injury (AKI). Doctors can only offer supportive care, like maintaining hydration and blood pressure, or resorting to dialysis while hoping the organ recovers on its own.

This lack of treatment options stands against a backdrop of rising global and domestic diagnoses:

The dramatic surge in U.S. cases over the last two decades highlights a critical vulnerability in inpatient care, frequently driven by severe infections (sepsis), major surgeries, or medication toxicities.

A Rare Victory for Publicly Funded Science

Beyond the biology, AD-NP1 represents a highly unusual achievement in modern pharmacology. The drug was developed from “bench to bedside”—from basic lab discovery to an FDA-approved clinical trial asset—entirely within an academic setting using public funds. Funding was provided by the National Institutes of Health (NIH), the Department of Defense (DoD), and the California Institute for Regenerative Medicine (CIRM), entirely bypassing the traditional early-stage private venture capital route.

Following successful safety and efficacy profiles in both mice and non-human primates, the FDA granted investigational new drug (IND) status to AD-NP1. Phase 1 clinical trials in humans officially commenced evaluating safety, appropriate dosing, and how the human body metabolizes the compound.

While these initial trials are strictly focused on patients recovering from heart attacks, Dr. Deb plans to apply for separate FDA approval to initiate human trials for kidney applications, pending the safety outcomes of the current cardiac studies.

Important Limitations and Scientific Caution

While these findings are undeniably exciting, outside medical experts urge the public to temper their expectations with standard clinical caution.

First, the kidney data relies entirely on mouse models. While AD-NP1 has demonstrated an acceptable safety profile in non-human primates, human biology is profoundly complex, and therapies that work perfectly in rodents frequently fail to translate effectively in human clinical trials.

Furthermore, because the drug has not yet been tested over long periods in humans, the long-term systemic effects of completely blocking the ENPP1 protein remain entirely unknown. It is also unclear whether this mechanism would offer any benefit to individuals suffering from long-term Chronic Kidney Disease (CKD) or diabetes-related kidney damage, as the study strictly evaluated acute, sudden organ injuries.

Dr. Deb’s team freely acknowledges these hurdles, emphasizing that confirming the drug’s efficacy and safety in human patients requires years of rigorous, controlled clinical testing.

What This Means for Consumers Today

For health-conscious readers, this study serves as a fascinating preview of the future of regenerative medicine, but it should not change how anyone manages their health today. Because AD-NP1 is years away from potential commercial approval for kidneys, standard preventative measures remain the gold standard for maintaining renal health.

Medical professionals continue to emphasize that the most effective ways to protect your kidneys include carefully managing blood pressure, strictly controlling blood sugar levels if diabetic, maintaining proper daily hydration, and avoiding the chronic, excessive use of over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, which can cause direct renal strain. Patients currently recovering from an episode of acute kidney injury should continue to strictly follow their healthcare provider’s customized care plans.

Reference Section

• https://www.reuters.com/business/healthcare-pharmaceuticals/experimental-first-in-class-heart-drug-may-also-help-heal-kidneys-2026-06-19/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.